Andreas Hünnemeyer

Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects

Bernhard Hauns, Róbert Hermann, Andreas Hünnemeyer et al. · The Journal of Clinical Pharmacology · 2006 · 45 citations

Nutrition, Oral Roflumilast 500, Healthy Subjects +14

Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

Gëzim Lahu, Andreas Hünnemeyer, E Diletti et al. · Clinical Pharmacokinetics · 2010 · 34 citations · Full text

Pharmacokinetic Modeling, Pharmacological Study, Pharmacology +8

The Targeted Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions

Gabriele M. Böhmer, Nassr Nassr, Marcus Wenger et al. · The Journal of Clinical Pharmacology · 2009 · 17 citations

Magnesium Hydroxide/Aluminium Hydroxide‐Containing Antacid Does Not Affect the Pharmacokinetics of the Targeted Phosphodiesterase 4 Inhibitor Roflumilast

Nassr Nassr, Gëzim Lahu, Andreas Hünnemeyer et al. · The Journal of Clinical Pharmacology · 2007 · 17 citations

Medicinal Chemistry, Biochemistry, Medicine +6

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study

T.D. Bethke, M. Hartmann, Andreas Hünnemeyer et al. · International Journal of Clinical Pharmacology and Therapeutics · 2011 · 14 citations